Spy Agent Green Kit Patent Expiration

Spy Agent Green Kit is a drug owned by Novadaq Technologies Ulc. It is protected by 9 US drug patents filed from 2018 to 2023. Out of these, 5 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2039. Details of Spy Agent Green Kit's patents and their expiration are given in the table below.

Patent strength
3
/ 10

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712320 Methods and systems to automate surgical interventions
Jul, 2039

(12 years from now)

Active
US10631746 Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
Aug, 2035

(8 years from now)

Active
US8406860 Method for evaluating blush in myocardial tissue
Apr, 2029

(2 years from now)

Active
US8647605 Real time imaging during solid organ transplant
Feb, 2029

(2 years from now)

Active
US8185176 Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
Jun, 2028

(1 year, 7 months from now)

Active
US9421280 Real time imaging during solid organ transplant
Nov, 2025

(10 months ago)

Expired
US7881777 Method and apparatus for performing intra-operative angiography
Sep, 2021

(5 years ago)

Expired
US6915154 Method and apparatus for performing intra-operative angiography
Aug, 2021

(5 years ago)

Expired
US8892190 Method and apparatus for performing intra-operative angiography
Aug, 2020

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Spy Agent Green Kit's patents.

Given below is the list of recent legal activities going on the following patents of Spy Agent Green Kit.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 29 Sep, 2025 US8647605
Payment of Maintenance Fee, 12th Year, Large Entity 11 Sep, 2024 US8406860
Payment of Maintenance Fee, 8th Year, Large Entity 07 Feb, 2024 US9421280
Payment of Maintenance Fee, 12th Year, Large Entity 08 Nov, 2023 US8185176
Payment of Maintenance Fee, 4th Year, Large Entity 11 Oct, 2023 US10631746
Mail Patent eGrant Notification 01 Aug, 2023 US11712320
Recordation of Patent eGrant 01 Aug, 2023 US11712320
Electronic Review 01 Aug, 2023 US11712320
Patent eGrant Notification 01 Aug, 2023 US11712320
Patent Issue Date Used in PTA Calculation 01 Aug, 2023 US11712320


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Spy Agent Green Kit and ongoing litigations to help you estimate the early arrival of Spy Agent Green Kit generic.

Spy Agent Green Kit's Litigations

Spy Agent Green Kit been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 22, 2017, against patent number US8892190. The petitioner Visionsense Corp., challenged the validity of this patent, with Novadaq Technologies Inc. as the respondent. Click below to track the latest information on how companies are challenging Spy Agent Green Kit's patents.

Last updated on October 6, 2026
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8892190 May, 2017 Terminated-Settled
(18 Apr, 2018)
Novadaq Technologies Inc. Visionsense Corp.


FDA has granted some exclusivities to Spy Agent Green Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Spy Agent Green Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Spy Agent Green Kit.

Exclusivity Information

Spy Agent Green Kit holds 2 exclusivities. All of its exclusivities have expired in 2026. Details of Spy Agent Green Kit's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 21, 2021
New Indication(I-911) Jun 05, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Spy Agent Green Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Spy Agent Green Kit's family patents as well as insights into ongoing legal events on those patents.

Spy Agent Green Kit's Family Patents

Spy Agent Green Kit has patent protection in a total of 12 countries. It's US patent count contributes only to 35.6% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Spy Agent Green Kit.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Spy Agent Green Kit:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Sentinel Node Biopsy in Endometrial Cancer Queensland Centre for Gynaecological Cancer NA RECRUITING
(Sep 1, 2026)
PHASE3
Indocyanine Green (ICG) Guided Tumor Resection St. Jude Children's Research Hospital NA COMPLETED
(Sep 1, 2026)
PHASE1
Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI) OPTOSURGICAL, LLC NA TERMINATED
(Sep 1, 2026)
PHASE1
Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery City of Hope Medical Center NA COMPLETED
(Aug 1, 2026)
PHASE1
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Institut de Cancérologie de Lorraine NA COMPLETED
(Aug 1, 2026)
PHASE3
A Study of Intra-operative Imaging in Women With Ovarian Cancer Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer M.D. Anderson Cancer Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1
Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship The University of Texas Health Science Center, Houston NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Xiang-Qian NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
ICG Fluorescence in Knee Arthroscopy Study Henry Ford Health System NA RECRUITING
(Aug 1, 2026)
PHASE1
Optimal Dosing of IC-Green for Visualization of Rotator Cuff Vascularity Using Advanced Imaging Modality Arthroscopy NYU Langone Health NA COMPLETED
(Jul 1, 2026)
PHASE1
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors Medical University of South Carolina NA RECRUITING
(Jul 1, 2026)
PHASE2
Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial City of Hope Medical Center NA RECRUITING
(Jun 1, 2026)
PHASE2
Intraoperative Tumor Margin Identification With ICG Dye Imaging Massachusetts General Hospital NA RECRUITING
(Apr 1, 2026)
PHASE2
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia Boston Children's Hospital NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2
TumorGlow Intraoperative Molecular Imaging (IMI) University of Pennsylvania NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging. Johns Hopkins University NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE1




Generic Launch

Generic Release Date:

Spy Agent Green Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 14, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Spy Agent Green Kit Generic API suppliers:

Indocyanine Green is the generic name for the brand Spy Agent Green Kit. 2 different companies have already filed for the generic of Spy Agent Green Kit, with Renew Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Spy Agent Green Kit's generic

How can I launch a generic of Spy Agent Green Kit before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Spy Agent Green Kit's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Spy Agent Green Kit's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Spy Agent Green Kit -

Strength Submission Date Expiration Date of Last Qualifying Patent 180-Day Status First Applicant Approval Generic Competition Status
25 mg / 5 mL
🔒 Unlock
28 Nov, 2022 04 Aug, 2035 Extinguished Less






About Spy Agent Green Kit

Spy Agent Green Kit is a drug owned by Novadaq Technologies Ulc. It is used for visualizing blood flow in various surgical procedures and organ transplants. Spy Agent Green Kit uses Indocyanine Green as an active ingredient. Spy Agent Green Kit was launched by Novadaq Tech in 2018.

Approval Date:

Spy Agent Green Kit was approved by FDA for market use on 21 November, 2018.

Active Ingredient:

Spy Agent Green Kit uses Indocyanine Green as the active ingredient. Check out other Drugs and Companies using Indocyanine Green ingredient

Treatment:

Spy Agent Green Kit is used for visualizing blood flow in various surgical procedures and organ transplants.

Dosage:

Spy Agent Green Kit is available in powder form for intravenous, interstitial use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
25MG/VIAL POWDER Prescription INTRAVENOUS, INTERSTITIAL